PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Artios, Novartis form cancer therapies collaboration

Artios Pharma and Novartis have formed a global research collaboration to discover and validate next generation DNA damage response (DDR) targets to enhance the Swiss drugmaker’s radioligand therapies (RLT).
Novartis’ RLT delivers targeted radiation to a specific subset of cancer cells, thus reducing harmful effects of treatment on the surrounding healthy cells. The firms note that RLT has been shown to improve overall survival and quality of life, particularly in cancers with bone metastases.
Under the three-year deal, Artios and Novartis will perform target discovery and validation, and Novartis will select up to three exclusive DDR targets, receiving worldwide rights to use them with its RLTs.
On the financial side, Novartis will make an upfront payment of $20 million and provide near term research funding to support the collaboration, while Artios stands to receive up to $1.3 billion in discovery, development, regulatory and sales-based milestones, in addition to royalty payments on net sales of products making it to market.
“This collaboration expands the reach of our discovery platform, leveraging our DDR expertise and target knowledge to enhance the potential of radioligand therapies,” commented Dr Niall Martin, Artios’ chief executive.
“From a strategic perspective, this collaboration is an ideal fit which maximises the application of our platform to areas beyond our current focus as we independently advance our pipeline of novel DDR candidates.”
The collaboration does not include Artios’ lead programs, ART0380, which is currently in clinical development, or ART4215, a first-in-class Pol Theta inhibitor.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026